Although recruiting the required 400 patients is expected to be difficult, since patients must be diagnosed earlier than usual and with relevant tumour mutations to be eligible, this is an important conceptual trial. Alongside moves to improve tumour diagnosis, classification and targeted treatment, research to show how best to deploy these new developments for patient benefit is critical. 

comments powered by Disqus